Animal Pharma innovators are actively looking at competent, reliable API/CDMO partners.
"We predict that the sourcing, partnering, development and funding of innovation will be more transformational and significant the next five years than ever before in animal health" - #Elanco
More from Sajal Kapoor
[Free CDMO Masterclass #18] https://t.co/208eQbYKEF
— Conviction | Patience (@unseenvalue) July 25, 2021
[Free Art of Investing] https://t.co/bHvUqnpiTE
[Paid IIC Dec 2020 on SeQuent] https://t.co/3iDO438Et9
[Charity fund raise on Unseen Trends in Biotechnology] https://t.co/eNi1x1qwhH
[Q&A on APIs] https://t.co/EQGz007a9S
More from Sequent
Market is short sighted and loves to buy high and sell low
Sequent is a long gestation stock, it won't deliver it's real earnings until FY23-25
Not suitable investment for those who want 100% return/yr
@itsTarH hey Tariq, any idea why is Sequent falling?
— Vivek (@pa_stock) September 27, 2021
https://t.co/7ytUeSd7gg
Don't expect the earnings to go anywhere till FY23.
— Tar \u26a1 (@itsTarH) August 10, 2021
Real growth will only come post FY24.
I expect the stock to either correct or stay muted till then. https://t.co/lUQfzxojTO
Having multiple facilities accredited with certifications from the best authorities from globe is a hidden moat in itself... 10-20% pop and then retracement should not shake confidence... Business focus and longevity should build conviction
— Harinder S Nanda (@harindersnanda) July 14, 2021
\U0001f436\U0001f431\U0001f434\U0001f42e\U0001f437\U0001f411@unseenvalue @soicfinance